States Allege Misleading Promises to New Parents
AUSTIN, TX & PHOENIX, AZ – In a significant move to protect vulnerable consumers, the attorneys general of Texas and Arizona have filed separate lawsuits against Cord Blood Registry (CBR), one of the nation's largest private umbilical cord blood banks. The lawsuits, filed independently on October 17, 2023, in state district courts, contend that CBR engaged in widespread deceptive advertising practices, profiting from misleading new parents about the medical benefits and likelihood of using their children's stored cord blood stem cells.
Texas Attorney General Ken Paxton and Arizona Attorney General Kris Mayes each accuse CBR of exploiting the hopes and anxieties of expectant parents, marketing their services with exaggerated claims regarding the current and future therapeutic applications of cord blood. The attorneys general allege that CBR's marketing materials, both online and in print, overstate the probability that a child or family member will ever need or be able to use the stored stem cells for established medical treatments, prompting families to pay thousands of dollars for a service based on false pretenses.
The Core of the Allegations: False Hope and High Costs
According to court documents filed by the states, CBR's marketing campaigns, active from at least early 2018 through mid-2023, allegedly presented speculative and experimental treatments as readily available and effective. Parents were reportedly led to believe that storing cord blood provided a comprehensive 'biological insurance policy' against a wide array of future diseases, including conditions like autism, cerebral palsy, and Alzheimer's disease, for which cord blood therapies are still largely experimental or unproven in routine clinical practice.
“New parents, navigating the overwhelming decisions surrounding their child’s future, deserve honest and transparent information, especially when it comes to medical services,” stated Attorney General Paxton in a press release. “CBR allegedly preyed on these emotions, promising a future that current science simply doesn’t support for the vast majority of families, all while charging exorbitant fees.”
The lawsuits detail how CBR allegedly utilized emotionally charged language and imagery to persuade parents to enroll in their service, which typically involves an initial collection and processing fee ranging from $1,500 to $2,500, followed by annual storage fees of approximately $175. Over a typical 20-year storage period, this can amount to nearly $6,000 per family, representing hundreds of millions in profit for CBR across tens of thousands of families nationwide.
Understanding Cord Blood Science vs. Marketing
Umbilical cord blood is a rich source of hematopoietic stem cells, which have proven efficacy in treating certain blood disorders, cancers, and immune system deficiencies, such as leukemia, lymphoma, and aplastic anemia. These established uses are generally well-documented and recognized by medical bodies. However, the probability of an individual child needing their own stored cord blood for such established therapies is exceedingly low, estimated to be between 1 in 400 and 1 in 200,000, depending on the specific condition and source of statistics.
“While the potential of stem cell research is exciting, it is crucial to differentiate between established medical treatments and ongoing clinical trials or speculative future applications,” Attorney General Mayes commented. “CBR’s marketing, as we allege, blurred these lines, presenting future possibilities as present realities and creating a false sense of urgency and necessity for parents.”
The lawsuits specifically point to CBR's claims regarding regenerative medicine, suggesting that cord blood could routinely treat conditions like diabetes or spinal cord injuries, areas where research is ongoing but standard clinical application is far from established. This alleged overpromotion, the states argue, misled parents into making significant financial investments based on unsubstantiated medical claims.
Legal Demands and Industry Impact
Both Texas and Arizona are seeking civil penalties, restitution for affected consumers, and injunctions to prevent CBR from engaging in further deceptive advertising practices. The lawsuits emphasize the need for greater transparency and accountability within the private cord blood banking industry, which has faced scrutiny from medical professionals and consumer advocacy groups for years regarding its marketing tactics.
As of press time, CBR, a subsidiary of CooperSurgical, Inc., had not issued a public statement regarding the lawsuits. This legal action could set a precedent for increased oversight of health-related services marketed directly to consumers, particularly those preying on parental instincts and hopes for their children’s well-being. The cases underscore the critical importance of families conducting thorough research and consulting with independent medical professionals before committing to elective health services with significant financial and emotional implications.
